Home › NDC Lookup › RxCUI directory › RxCUI 804544

Difluprednate 0.5 MG/ML Ophthalmic Suspension — RxCUI 804544

RxNorm drug concept · Semantic clinical drug
RxCUI 804544 Semantic clinical drug · SCD ● Current RxNorm concept 11 FDA products 11 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI804544
Official nameDifluprednate 0.5 MG/ML Ophthalmic Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asdifluprednate 0.05 % Ophthalmic Emulsion
FDA products mapped11
Package NDCs mapped11
Reported Medicaid activity (SDUD)14,855 prescriptions · 39 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Difluprednate Ophthalmic: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Difluprednate ophthalmic emulsion is a steroid eye drop used for two things: reducing inflammation and pain in the eye after eye surgery, and treating a condition called anterior u...
  • Start by removing your contact lenses — the preservative in these drops can soak into soft lenses. Tilt your head back, pull down your lower eyelid, and place one drop inside. Try...
  • Some mild side effects are common and usually settle down, including eye redness, light sensitivity, eye pain, blurred vision, and some irritation or crusting around the eyelid. Th...
  • What side effects should I expect, and which ones mean I should call my doctor?
📖 Read our full Difluprednate Ophthalmic guide →

🕸️ Concept Web — How Difluprednate 0.5 MG/ML Ophthalmic Suspension Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Difluprednate 0.5 MG/ML Ophthalmic Suspension RxCUI 804544

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Difluprednate 23043
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Durezol 802597
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Difluprednate Ophthalmic Suspension 804543
    • Difluprednate Ophthalmic Product 1158903
    • Difluprednate Ophthalmic Suspension [Durezol] 804546
    • Durezol Ophthalmic Product 1168936
    • Ophthalmic Suspension 316964
    • Ophthalmic Product 1151135
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Difluprednate 0.5 MG/ML SCDC · 802626
  • Difluprednate Ophthalmic Suspension SCDF · 804543
  • Difluprednate Ophthalmic Product SCDG · 1158903

Brand-Name Concepts

📦 FDA Products & Package NDCs

11 products · 11 package NDCs
11 package NDCs map to RxCUI 804544 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00378-7518-35 1 BOTTLE in 1 CARTON (0378-7518-35) / 5 mL in 1 BOTTLE Difluprednate Mylan Pharmaceuticals Inc. 2025-09-26
00781-6000-78 1 BOTTLE in 1 CARTON (0781-6000-78) / 5 mL in 1 BOTTLE Difluprednate Ophthalmic Sandoz Inc 2021-09-15
00832-6054-05 1 BOTTLE in 1 CARTON (0832-6054-05) / 5 mL in 1 BOTTLE Difluprednate Upsher-Smith Laboratories, LLC 2025-08-21
43598-0588-11 1 BOTTLE in 1 CARTON (43598-588-11) / 5 mL in 1 BOTTLE Difluprednate Ophthalmic Emulsion Dr. Reddy's Laboratories Inc. 2022-12-25
46708-0750-05 1 BOTTLE in 1 CARTON (46708-750-05) / 5 mL in 1 BOTTLE Difluprednate Alembic Pharmaceuticals Limited 2026-01-26
62332-0750-05 1 BOTTLE in 1 CARTON (62332-750-05) / 5 mL in 1 BOTTLE Difluprednate Alembic Pharmaceuticals Inc. 2026-01-26
65145-0161-01 1 BOTTLE in 1 CARTON (65145-161-01) / 5 mL in 1 BOTTLE Difluprednate Caplin Steriles Limited 2024-12-26
66758-0086-75 1 BOTTLE in 1 CARTON (66758-086-75) / 5 mL in 1 BOTTLE DUREZOL Sandoz Inc 2024-12-06
69097-0341-35 1 BOTTLE in 1 CARTON (69097-341-35) / 5 mL in 1 BOTTLE DIFLUPREDNATE Cipla USA Inc. 2021-08-09
69238-1380-03 1 BOTTLE in 1 CARTON (69238-1380-3) / 5 mL in 1 BOTTLE Difluprednate Amneal Pharmaceuticals NY LLC 2021-11-18
69315-0329-05 1 BOTTLE in 1 CARTON (69315-329-05) / 5 mL in 1 BOTTLE DIFLUPREDNATE Leading Pharma, LLC 2025-02-18
Observed labelers: Sandoz Inc (2) · Alembic Pharmaceuticals Inc. (1) · Alembic Pharmaceuticals Limited (1) · Amneal Pharmaceuticals NY LLC (1) · Caplin Steriles Limited (1) · Cipla USA Inc. (1) · +4 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ml · median
$7.0479
Range $7.0479–$42.3207 · middle 50% $7.0479–$7.0479 · 9 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.